LONDON, January 21, 2019 /PRNewswire/ --
BTG plc (LSE: BTG), a global specialist healthcare company,
today announced the treatment of an Australian patient with DC Bead
LUMI™, a next-generation development of the market leading DC
Bead®. DC Bead LUMI™ is the first commercially available
Radiopaque Drug-Eluting Bead which can be loaded with doxorubicin
or irinotecan for the local treatment of tumours in patients with
hepatocellular carcinoma (HCC) and liver metastases from colorectal
cancer (mCRC), respectively.
(Logo:
https://mma.prnewswire.com/media/513730/BTG_IO_Logo.jpg )
DC Bead LUMI™ offers a personalised approach to treatment and a
new level of control to TACE procedures. The lasting radiopacity
allows the physician to see rather than assume where the beads are
placed in the tumour, providing reassurance to patients that the
treatment is getting to where it needs to be.
Dr Anthony Wilkinson, BTG
Regional Medical Director commented, "Feedback from both physicians
and their patients indicate that DC Bead LUMI™ is an important
advance in personalised, loco-regional cancer therapy. As a leader
in intra-hepatic therapy for HCC, BTG is excited to be able to
launch our latest Drug-Eluting Bead product in the Australian
market. We anticipate that the enhanced visualisation of DC Bead
LUMI™ will lead to improved patient outcomes through more accurate
delivery."
At the Wesley Hospital, Brisbane, Diagnostic and Interventional
Radiologist Dr Duncan Walker and his
team performed transarterial chemoembolisation (TACE) using DC Bead
LUMI™ on a patient with liver tumours. Dr. Walker commented, "DC
Bead LUMI™ gave me added confidence with clear, real-time evidence
on the treatment of the target lesion. The long-term
radiopacity allows us to see where we're delivering the treatment
during the procedure and identifies areas of treatment in follow up
scans."
Camilla Roder, Sr Product Manager, Device Technologies said,
"We're proud to partner with BTG to offer a new and innovative
treatment option for patients. We look forward to providing DC
Bead LUMI™ to more clinicians across Australia."
DC Bead LUMI™ gained Class III CE Mark certification in early
March, 2017.
About BTG Interventional Oncology
BTG Interventional Oncology is committed to improving patient
outcomes and experience with Minimally Invasive, Personalized
Solutions (MIPS). Our products are used to treat or provide
symptomatic relief for people with cancer and benign tumours. To
learn more about BTG Interventional Oncology, please follow @BTGIO
on Twitter or visit btg-io.com
About DC Bead LUMI™
DC Bead LUMI™ is the first commercially available radiopaque
drug-eluting bead (DEB) which can be loaded with doxorubicin or
irinotecan for the local treatment of tumours in patients with
hepatocellular carcinoma (HCC) and malignant colorectal cancer
metastasised to the liver (mCRC). DC Bead LUMI™ are precisely
calibrated, radiopaque DEB developed using the same core chemistry
as the clinically proven DC Bead®. DC Bead LUMI™ contain
a covalently bound radiopaque moiety to offer inherent, lasting
radiopacity; they are visible under imaging (computed tomography
[CT], cone-beam computed tomography [CBCT] and fluoroscopy)
providing visible confirmation of bead location during embolisation
procedures. The lasting radiopacity of DC Bead LUMI™ means they
will also be visible in follow-up scans. For more information,
please visit: dcbeadlumi.com.
About DC Bead®
DC Bead® is the only drug-eluting bead with CE Mark
approval for loading with doxorubicin or irinotecan, providing an
effective standardised liver-directed therapy for primary and
metastatic liver cancer. With more than ten years' clinical
experience, extensive peer-review evidence supports the benefits
offered by the unique chemistry of DC Bead®. In
intermediate HCC, these benefits include improved tolerability and
tumour response versus cTACE and high rates of five-year
survival.[1]-[5]
In metastatic colorectal cancer patients, DC Bead® has
been shown to offer improved survival and enhanced quality of life
versus systemic chemotherapy
alone.[6] For instructions for use
and important safety information, please visit: dcbead.com.
References:
- Lammer J et al. Cardiovasc Intervent Radiol 2010; 33:
41-52.
- Song MJ et al. Eur J Gastroenterol Hepatol 2011; 23:
521-7.
- Dhanasakeran R et al. J Surg Oncol 2010; 101: 476-80.
- Burrel M et al. J Hepatol 20 12; 56: 1330-5.
- Malagari K et al. Cardiovasc Intervent Radiol 2012; 35:
1119-28.
- Fiorentini G et al. Anticancer Res 2012; 32: 1387.
For further information contact:
BTG
Chris Sampson
Corporate Communications Director
+44(0)20-7575-1595
SOURCE BTG plc